

## Medical Coverage Policy | Intravitreal and Punctum Corticosteroid Implants



**EFFECTIVE DATE:** 10|01|2015

**POLICY LAST UPDATED:** 07|02|2020

### OVERVIEW

An intravitreal implant is a drug delivery system, injected or surgically implanted in the vitreous of the eye, for sustained release of drug to the posterior and intermediate segments of the eye. Intravitreal corticosteroid implants are being investigated for a variety of inflammatory eye conditions.

### MEDICAL CRITERIA

Not applicable

### PRIOR AUTHORIZATION

Prior authorization review is not required.

### POLICY STATEMENT

#### BlueCHiP for Medicare and Commercial Products

A fluocinolone acetonide intravitreal implant 0.59 mg (Retisert®) may be considered medically necessary for the treatment of chronic noninfectious intermediate, posterior, or panuveitis

A fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien®) may be considered medically necessary for the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

A dexamethasone intravitreal implant 0.7 mg (Ozurdex™) may be considered medically necessary for the treatment of:

- Noninfectious ocular inflammation, or uveitis, affecting the intermediate or posterior segment of the eye, OR
- Macular edema following branch or central retinal vein occlusion, OR
- Diabetic macular edema.

A punctum dexamethasone insert 0.4 mg (Dextenza®) may be considered medically necessary with ocular inflammation and pain following ophthalmic surgery

A fluocinolone acetonide intravitreal implant 0.59 mg (Retisert®) or 0.19 mg (Iluvien®) or dexamethasone intravitreal implant 0.7 mg (Ozurdex™) is considered not covered for BlueCHiP for Medicare and not medically necessary for Commercial Products for the treatment of:

- Birdshot retinochoroidopathy
- Cystoid macular edema related to retinitis pigmentosa
- Idiopathic macular telangiectasia type 1
- Postoperative macular edema
- Circumscribed choroidal hemangiomas
- Proliferative vitreoretinopathy
- Radiation retinopathy.
- Prophylaxis of cystoid macular edema in patients with noninfectious intermediate uveitis or posterior uveitis and cataract undergoing cataract surgery

A fluocinolone acetonide intravitreal implant 0.18 mg (Yutiq®) is considered not covered for BlueCHiP for Medicare and not medically necessary for Commercial Products for the treatment of chronic noninfectious posterior uveitis affecting the posterior segment of the eye

### **BlueCHiP for Medicare**

All other uses of a corticosteroid intravitreal implant are considered not covered there is insufficient peer-reviewed scientific literature that demonstrates that the procedure/service is effective.

### **Commercial Products**

All other uses of a corticosteroid intravitreal implant are considered not medically necessary as there is insufficient peer-reviewed scientific literature that demonstrates that the procedure/service is effective.

### **COVERAGE**

Benefits may vary between groups and contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for applicable physician administered injectable drug benefits/coverage.

### **BACKGROUND**

An intravitreal implant is a drug delivery system, injected or surgically implanted in the vitreous of the eye, for sustained release of a pharmacologic agent to the posterior and intermediate segments of the eye. Three intravitreal corticosteroid implants, ie, fluocinolone acetonide 0.59 mg (Retisert), fluocinolone acetonide 0.19 mg (Iluvien), and dexamethasone 0.7 mg (Ozurdex) are reviewed herein. Fluocinolone acetonide implants are nonerodible and deliver drug up to 30 to 36 months while dexamethasone implants are bioerodible and last up to 6 months.

A punctum implant is a drug delivery device that is inserted through the lower lacrimal punctum into the canaliculus, for sustained release of a pharmacologic agent to the ocular surface. Dexamethasone ophthalmic insert 0.4 mg (Dextenza) is the first corticosteroid intracanalicular insert and is reviewed herein.

### **Uveitis**

For individuals with chronic noninfectious intermediate or posterior uveitis who receive an intravitreal fluocinolone acetonide implant (0.59 mg), the evidence includes 4 randomized controlled trials (RCTs). Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Two of the 4 RCTs compared 2 doses of implants, and 2 trials compared implants with systemic steroids (and immunosuppression when indicated). All trials supported the efficacy of intravitreal fluocinolone acetonide implants in preventing recurrence and improving visual acuity over 4-year follow-up. The head-to-head trial comparing implants with systemic corticosteroids did not show substantial superiority in the overall effectiveness of either approach. After 24 and 54 months of follow-up, visual acuity improved from baseline in the implant groups compared with the systematic therapy groups by +6.0 and +3.2 letters ( $p=0.16$ ) and +2.4 and 3.1 letters ( $p=0.073$ ), respectively. However, nearly all phakic patients receiving implants developed cataracts and required cataract surgery. Further, most also developed glaucoma, with 75% of patients requiring intraocular pressure lowering medications and 35% requiring filtering surgeries. Systemic adverse events such as hyperlipidemia, diabetes, osteoporosis, fractures, and blood count/chemistry abnormalities were infrequent and not statistically distinguishable between groups. The incidence of hypertension was greater in the systemic therapy group (27%) than in the implant group (13%), but rates of antihypertensive treatment initiation did not differ. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with noninfectious intermediate or posterior uveitis who receive an intravitreal dexamethasone implant (0.7 mg), the evidence includes an RCT. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Results of this trial at 8 weeks showed that the implant was effective in reducing inflammation (the proportion of eyes with no

inflammation was 47% and 12% with implant and sham, respectively) and resulted in clinically meaningful improvement in vision at week 8 compared with sham controls (the proportion of patients with a gain of  $\geq 15$  letters in best-corrected visual acuity from baseline was  $\gg 40\%$  with implants and 10% with sham). Further, at week 26, patients treated with implants reported meaningful increases in vision-related functioning. The major limitation of this trial was its lack of long-term follow-up. Use of implants resulted in higher incidences of cataracts and elevated intraocular pressure. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with chronic noninfectious posterior uveitis affecting the posterior segment of the eye and who receive intravitreal fluocinolone acetonide implant (0.18 mg, Yutiq), the evidence includes 2 pivotal RCTs. Relevant outcomes are symptom improvement, change in disease status, functional status and quality of life. Harmful outcomes of interest are treatment-related morbidity. Both RCTs consistently found statistically significantly lower uveitis recurrence rates for intravitreal fluocinolone acetonide implant (0.18 mg, Yutiq) at both 6 and 12 months. However, serious limitations of these findings include inconsistency in the magnitude of the benefit at 12 months (odds ratio 67.09; 95% confidence interval 8.81-511.06 in published RCT and odds ratio 3.04; 95% confidence interval 1.52, 6.08 in the unpublished RCT) and, with more imputed recurrences in the sham groups than the treatment groups, we also can't rule out an overestimation of the treatment effect. For the remainder of key outcomes, results were inconsistent between RCTs, appearing more favorable in the published trial. Most notable were the differences between RCTs in mean change in best-corrected visual acuity at 12 months (higher for fluocinolone acetonide in the published trial, lower in the unpublished trials) and risk of increased intraocular pressure within 12 months (increased risk in the unpublished trial, but not in the published trial). Due to these inconsistencies and serious methodological limitations, the evidence is insufficient to determine the effects of the technology on health outcomes.

### **Macular Edema**

For individuals with macular edema after retinal vein occlusion who receive an intravitreal dexamethasone implant (0.7 mg), the evidence includes 2 RCTs. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Compared with sham controls, implants resulted in clinically meaningful improvements in visual acuity within 1 to 3 months postimplant and improvement in vision occurred faster. The difference in the proportion of patients with gain of 15 or more letters in best-corrected visual acuity from baseline was more than 10% in favor implants versus sham in both studies at 30, 60 and 90 days, but not at 180 days postimplant. Use of implants resulted in higher incidences of cataracts and elevated intraocular pressure. Several additional RCTs and a meta-analysis have evaluated the comparative effects of dexamethasone intravitreal implants versus other therapies and found mixed results. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with macular edema after retinal vein occlusion who receive an intravitreal fluocinolone acetonide implant (0.59 mg), no studies were identified. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Diabetic Macular Edema**

For individuals with refractory (persistent or recurrent) diabetic macular edema who receive an intravitreal fluocinolone acetonide implant (0.59 mg), the evidence includes an RCT. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Compared with the standard of care (as needed laser or observation), a greater proportion of patients with implants reported clinically significant improvement in vision at 6 months (1.4% vs. 16.8% respectively) and subsequent time points assessed but not at or beyond 30 months of follow-up. Ninety percent of patients with phakic eyes who received implants required cataract surgery, and 60% developed elevated intraocular pressure. Due to the

substantial increase in adverse events and availability of agents with better tolerability profiles (eg, antivascular endothelial growth factor inhibitors), implant use in diabetic macular edema is questionable. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with diabetic macular edema who receive an intravitreal fluocinolone acetonide implant (0.19 mg), the evidence includes 2 RCTs. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Implant-treated eyes showed clinically meaningful improvements in the vision at 2 and 3 years postimplant. The percentage of patients who gained 15 letters or more was 28.7% in the implant group versus 18.9% in the sham group at 3 years. Subgroup analysis showed greater improvements in visual acuity in patients who were pseudophakic compared with those who were phakic (difference in mean change in number of letters at 2 years from baseline was 5.6 letters in pseudophakic patients vs. 1 letter in phakic patients). A major limitation of these implants is that nearly 80% of all phakic patients will develop cataracts and will require cataract surgery. Further, intraocular pressure was elevated in 34% of patients who received this implant compared with 10% of controls. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with diabetic macular edema who receive an intravitreal dexamethasone implant (0.7 mg), the evidence includes 3 RCTs. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Compared with sham control, 2 identically designed RCTs showed clinically meaningful improvements in vision with dexamethasone implants that peaked at 3 months and maintained 39 months (with retreatment). The difference in the proportion of patients with a gain of 15 or more letters in best-corrected visual acuity from baseline was 9.3% and 13.0% in the 2 trials, respectively, favoring implant versus sham at 39 months postimplant. Subgroup analysis of these trials showed greater improvements in visual acuity in patients who were pseudophakic compared with those who were phakic. Additionally, evidence from various small and/or short-term trials and retrospective studies have found that, compared with primarily antivascular endothelial growth factor treatments, intravitreal dexamethasone implant (0.7 mg) was consistently associated with larger reductions in retinal thickness, but visual acuity changes were similar between treatment groups. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with diabetic macular edema who receive an intravitreal dexamethasone implant (0.7 mg) plus antivascular endothelial growth factor therapy, the evidence includes 2 RCTs. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Findings from both RCTs were consistent in demonstrating that although adding dexamethasone to an antivascular endothelial growth factor treatment can lead to a greater mean reduction in central subfield thickness, it does not improve visual acuity and can lead to a higher risk of intraocular pressure elevation. Based on the consistent lack of improvement in visual acuity, increased risk of intraocular pressure elevation, and imprecision, these RCTs provide insufficient evidence to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with diabetic macular edema who receive an intravitreal dexamethasone implant (0.7 mg) plus laser photocoagulation, the evidence includes an RCT. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. One RCT with 1-year follow-up demonstrated that combination implants plus laser photocoagulation compared with laser photocoagulation alone resulted in better visual acuity (as measured by a gain of  $\geq 10$  letters) at 9 months but not at 12 months. However, the generally accepted standard outcome measure for change is 15 or more letters, and this standard was not used in this trial. The use of dexamethasone implants resulted in higher incidences of cataracts and elevated intraocular pressure. Further, a differential loss to follow-up, lack of power calculations for sample size estimation, and lack of intention-to-treat analysis preclude interpretation of results. A larger RCT with adequate power is needed to confirm these findings. The evidence is insufficient to determine the effects of the technology on health outcomes.

## Age-Related Macular Degeneration

For individuals with age-related macular degeneration who receive an intravitreal dexamethasone implant (0.7 mg) plus antivascular endothelial growth factor inhibitor, the evidence includes an RCT. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Results of this trial did not demonstrate clinically meaningful reductions in the ranibizumab injection-free interval between combined treatments (34 days) and antivascular endothelial growth factor alone (29 days;  $p=0.016$ ). Further, intraocular pressure was elevated in a greater proportion of patients receiving implants without any additional clinical benefit. The evidence is insufficient to determine the effects of the technology on health outcomes.

## Other Conditions

For individuals with birdshot retinochoroidopathy refractory or intolerant to standard therapy who receive an intravitreal fluocinolone acetonide implant (0.59 mg) or intravitreal dexamethasone implant (0.7 mg), the evidence includes multiple observational studies. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Multiple observational studies have noted improvements in anatomic and visual acuity outcomes. Long-term follow-up for efficacy and safety is limited. RCTs are needed to permit conclusions on the efficacy of corticosteroid implants in patients with refractory or intolerant birdshot retinopathy. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with cystoid macular edema related to retinitis pigmentosa who receive an intravitreal dexamethasone implant (0.7 mg), the evidence includes a small observation-controlled RCT, a small prospective, oral acetazolamide-controlled cohort study, and multiple case reports. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Studies have noted mixed results for anatomic and visual acuity outcomes. Long-term follow-up for efficacy and safety is limited. Larger RCTs are needed to permit conclusions on the efficacy of corticosteroid implants in patients with cystoid macular edema related to retinitis pigmentosa. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with idiopathic macular telangiectasia type 1 who receive an intravitreal dexamethasone implant (0.7 mg), the evidence includes multiple case reports. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Case reports have noted mixed results for visual acuity and inflammation-related outcomes. Long-term follow-up for efficacy and safety is limited. Better quality studies with long-term follow-up are needed to permit conclusions on the efficacy of corticosteroid implants in patients with idiopathic macular telangiectasia type 1. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with postoperative chronic macular edema who receive an intravitreal dexamethasone implant (0.7 mg), the evidence includes multiple observational studies. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Among the multiple observational studies, a large retrospective analysis of 100 patients showed that 2 of every 5 patients experienced clinically meaningful improvements in the vision at 1-year follow-up. An RCT is needed to confirm the efficacy of corticosteroid implants in patients with postoperative chronic macular edema. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with circumscribed choroidal hemangiomas who receive an intravitreal dexamethasone implant (0.7 mg) plus photodynamic therapy, the evidence includes a case report. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Results of the case report do not permit conclusions about the efficacy or safety of adding dexamethasone

implants for circumscribed choroidal hemangiomas to photodynamic therapy. RCTs are needed to permit conclusions on the efficacy of corticosteroid implants in this population. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with proliferative vitreoretinopathy who receive an intravitreal dexamethasone implant (0.7 mg), the evidence includes a case series and a case report. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. These studies have reported multiple interventions, including dexamethasone implants in conjunction with surgery and laser for preventing proliferative retinopathy after retinal detachment surgery. RCTs are needed to permit conclusions on the efficacy of corticosteroid implants in patients with proliferative retinopathy. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with radiation retinopathy who receive an intravitreal dexamethasone implant (0.7 mg), the evidence includes multiple observational studies. Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life, and treatment-related morbidity. Multiple observational studies have noted improvements in anatomic and visual acuity outcomes. Long-term follow-up for efficacy and safety is limited. RCTs are needed to permit conclusions on the efficacy of corticosteroid implants in patients with radiation retinopathy. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals scheduled to undergo clear corneal cataract surgery who receive punctum dexamethasone insert (0.4 mg), the evidence includes 3 RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. All 3 trials noted significant improvements with the punctum dexamethasone insert (0.4 mg) across both coprimary efficacy endpoints of absence of pain at 8 days and absence of anterior chamber cells at day 14. Adverse events were generally similar between punctum dexamethasone insert (0.4 mg) and sham. Based on the consistent benefits and lack of important increases in adverse event risk, evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with noninfectious intermediate uveitis or posterior uveitis and cataract undergoing cataract surgery who receive prophylaxis with intravitreal dexamethasone 0.7 mg (Ozurdex), the best evidence includes 1 single-center, open-label RCT of 43 patients in India. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Compared with oral corticosteroids, intravitreal dexamethasone 0.7 mg had similar benefits and avoided need for early steroid taper due to adverse effects on blood glucose, but potentially increased risk of developing intraocular pressure. Due to important study limitations including its small sample size, unclear allocation concealment methods and lack of blinding, evidence is insufficient to determine that the technology results in a meaningful improvement in the net health outcome.

## **CODING**

### **BlueCHiP for Medicare and Commercial Products**

The following codes are covered when filed with an approved diagnosis noted below:

**J7311** Fluocinolone acetonide, intravitreal implant

**J7312** Injection, dexamethasone, intravitreal implant, 0.1 mg

**J7313** Injection, fluocinolone acetonide, intravitreal implant, 0.01 mg

**J7314** Injection, fluocinolone acetonide, intravitreal implant (Yutiq), 0.01 mg (effective 10/1/2019)

### **Medically necessary ICD-10 diagnosis**

H30.90-H30.93

H34.8110-H34.8192

H34.8310-H34.8392

H35.81

## RELATED POLICIES

Suprachoroidal Delivery of Pharmacologic Agents

## PUBLISHED

Provider Update, September 2020

Provider Update, August 2019

Provider Update, October 2018

Provider Update, April 2017

Provider Update, January 2017

Provider Update, August 2015

## REFERENCES

1. Haller JA, Bandello F, Belfort R, Jr., et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. *Ophthalmology*. Jun 2010;117(6):1134-1146 e1133. PMID 20417567
2. Haller JA, Bandello F, Belfort R, Jr., et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. *Ophthalmology*. Dec 2011;118(12):2453-2460. PMID 21764136
3. Bausch & Lomb Incorporated. Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg: Prescribing Label. 2019; <https://www.bausch.com/Portals/69/-/m/BL/United%20States/USFiles/Package%20Inserts/Pharma/retisert-prescribing-information.pdf?ver=2018-04-23-125740-133>. Accessed January 27, 2020.
4. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. *Ophthalmology*. Jun 2006;113(6):1020-1027. PMID 16690128
5. U.S. Food and Drug Administration. Center for Drug Evaluation and Research, Application number 21-737, Medical Review. 2005; [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2005/021737s000\\_MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021737s000_MedR.pdf). Accessed January 27, 2020.
6. Pavesio C, Zierhut M, Bairi K, et al. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. *Ophthalmology*. Mar 2010;117(3):567-575, 575 e561. PMID 20079922
7. Brady CJ, Villanti AC, Law HA, et al. Corticosteroid implants for chronic non-infectious uveitis. *Cochrane Database Syst Rev*. Feb 12 2016;2:CD010469. PMID 26866343
8. Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. *Ophthalmology*. Oct 2011;118(10):1916-1926. PMID 21840602
9. Multicenter Uveitis Steroid Treatment Trial Research Group. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty- four-month results of the Multicenter Uveitis Steroid Treatment (MUST) trial and follow-up study. *Ophthalmology*. Oct 2015;122(10):1967-1975. PMID 26298715
10. Multicenter Uveitis Steroid Treatment Trial Follow-up Study Research Group. Quality of life and risks associated with systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, or panuveitis: fifty-four-month results of the Multicenter Uveitis Steroid Treatment trial and follow-up study. *Ophthalmology*. Oct 2015;122(10):1976-1986. PMID 26298718

11. Holbrook JT, Sugar EA, Burke AE, et al. Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. *Am J Ophthalmol.* Apr 2016;164:29-36. PMID 26748056
12. Lowder C, Belfort R, Jr., Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. *Arch Ophthalmol.* Jan 10 2011;129(5):545-553. PMID 21220619
13. Lightman S, Belfort R, Jr., Naik RK, et al. Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. *Invest Ophthalmol Vis Sci.* Jul 2013;54(7):4864-4870. PMID 23761087
14. Gillespie BW, Musch DC, Niziol LM, et al. Estimating minimally important differences for two vision-specific quality of life measures. *Invest Ophthalmol Vis Sci.* Jun 06 2014;55(7):4206-4212. PMID 24906863
15. Allergan Inc. Ozurdex (dexamethasone intravitreal implant): Prescribing Label 2014; <https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/product-prescribing/20180515-OZURDEX-USPI-v1-0USPI3348.pdf>. Accessed January 27, 2020.
16. Jaffe GJ, Foster CS, Pavesio CE, et al. Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment: Twelve-Month Results. *Ophthalmology.* 2019 Apr;126(4). PMID 30367884
17. U.S. Food and Drug Administration. Center for Drug Evaluation and Research, Application number 210331, Medical Review. 2018; [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2018/210331Orig1s000MedR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210331Orig1s000MedR.pdf). Accessed January 24, 2020.
18. Yeh S, Kim SJ, Ho AC, et al. Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology. *Ophthalmology.* Apr 2015;122(4):769-778. PMID 25576994
19. Pichi F, Specchia C, Vitale L, et al. Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion. *Am J Ophthalmol.* Mar 2014;157(3):607-615 e601. PMID 24528934
20. Maturi RK, Chen V, Raghinaru D, et al. A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion. *Clin Ophthalmol.* Jun 2014;8:1057- 1064. PMID 24940042
21. Gado AS, Macky TA. Dexamethasone intravitreal implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. *Clin Experiment Ophthalmol.* Sep-Oct 2014;42(7):650-655. PMID 24612095
22. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreal dexamethasone drug delivery system in patients with persistent macular edema. *Arch Ophthalmol.* Mar 2007;125(3):309-317. PMID 17353400
23. Kumar P, Sharma YR, Chandra P, et al. Comparison of the Safety and Efficacy of Intravitreal Ranibizumab with or without Laser Photocoagulation Versus Dexamethasone Intravitreal Implant with or without Laser Photocoagulation for Macular Edema Secondary to Branch Retinal Vein Occlusion. *Folia Med (Plovdiv).* 2019 Jun;61(2). PMID 31301668
24. Ji K, Zhang Q, Tian M, et al. Comparison of dexamethasone intravitreal implant with intravitreal anti-VEGF injections for the treatment of macular edema secondary to branch retinal vein occlusion: A meta-analysis. *Medicine (Baltimore).* 2019 May;98(22). PMID 31145307
25. Thorne JE, Sugar EA, Holbrook JT, et al. Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. *Ophthalmology.* 2019 Feb;126(2). PMID 30269924
26. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. *Cochrane Database Syst Rev.* Jan 23 2008(1):CD005656. PMID 18254088



27. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. *Ophthalmology*. Aug 2011;118(8):1580-1587. PMID 21813090
28. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. *Ophthalmology*. Apr 2011;118(4):626-635 e622. PMID 21459216
29. Alimera Sciences Inc. Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg for Intravitreal Injection: Prescribing Label. 2014; [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/201923s002lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201923s002lbl.pdf). Accessed January 27, 2020.
30. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. *Ophthalmology*. Oct 2012;119(10):2125- 2132. PMID 22727177
31. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. *Ophthalmology*. Oct 2014;121(10):1892-1903. PMID 24935282
32. Massin P, Erginay A, Dupas B, et al. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. *Clin Ophthalmol*. Jul 2016;10:1257-1264. PMID 27468222
33. Boyer DS, Yoon YH, Belfort R, Jr., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. *Ophthalmology*. Oct 2014;121(10):1904-1914. PMID 24907062
34. Maturi RK, Glassman AR, Liu D, et al. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. *JAMA Ophthalmol*. 2018 Jan;136(1). PMID 29127949
35. Bolukbasi S, Cakir A, Erden B, et al. Comparison of the short-term effect of aflibercept and dexamethasone implant on serous retinal detachment in the treatment of naive diabetic macular edema. *Cutan Ocul Toxicol*. 2019 Dec;38(4). PMID 31438736
36. Cakir A, Erden B, Bolukbasi S, et al. Comparison of the effect of ranibizumab and dexamethasone implant in diabetic macular edema with concurrent epiretinal membrane. *J Fr Ophtalmol*. 2019 Sep;42(7). PMID 31088741
37. Coelho J, Malheiro L, Melo Beirao, J et al. Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes. *Clin Ophthalmol*. 2019;13:1751-1759. PMID 31571814
38. U.S. National Library of Medicine. Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema (DIME) NCT02471651. 2019. <https://clinicaltrials.gov/ct2/show/results/NCT02471651?term=NCT02471651&draw=2&rank=1> Accessed January 23, 2020.
39. Maturi RK, Bleau L, Saunders J, et al. A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-VEGF injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. *Retina*. Mar 30 2015;35(8):1604-1614. PMID 25829346
40. Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. *Ophthalmology*. Sep 2013;120(9):1843-1851. PMID 23706947
41. Kuppermann BD, Goldstein M, Maturi RK, et al. Dexamethasone intravitreal implant as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration: a multicenter randomized controlled trial. *Ophthalmologica*. Sep 2015;234(1):40-54. PMID 26088793
42. Bajwa A, Aziz K, Foster CS. Safety and efficacy of fluocinolone acetonide intravitreal implant (0.59 mg) in birdshot retinochoroidopathy. *Retina*. Nov 2014;34(11):2259-2268. PMID 24999722

43. Burkholder BM, Wang J, Dunn JP, et al. Postoperative outcomes after fluocinolone acetonide implant surgery in patients with birdshot chorioretinitis and other types of posterior and panuveitis. *Retina*. Sep 2013;33(8):1684- 1693. PMID 23549097
44. Rush RB, Goldstein DA, Callanan DG, et al. Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device. *Am J Ophthalmol*. Apr 2011;151(4):630-636. PMID 21277557
45. Srour M, Querques G, Leveziel N, et al. Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa. *Graefes Arch Clin Exp Ophthalmol*. Jun 2013;251(6):1501-1506. PMID 23275039
46. Erdogan G, Aydogan T, Unlu C, et al. Dexamethasone Implant for the treatment of type 1 idiopathic macular telangiectasia. *J Ocul Pharmacol Ther*. May 2016;32(4):211-215. PMID 26985700
47. Park UC, Park JH, Ma DJ et al. A RANDOMIZED PAIRED-EYE TRIAL OF INTRAVITREAL DEXAMETHASONE IMPLANT FOR CYSTOID MACULAR EDEMA IN RETINITIS PIGMENTOSA. *Retina (Philadelphia, Pa.)*. 2019 Jun. PMID 31166248
48. Veritti D, Sarao V, De Nadai K, et al. Dexamethasone Implant Produces Better Outcomes than Oral Acetazolamide in Patients with Cystoid Macular Edema Secondary to Retinitis Pigmentosa. *J Ocul Pharmacol Ther*. 2019 Dec. PMID 31886707
49. Ornek N, Ornek K, Erbahceci IE. Intravitreal dexamethasone implant (Ozurdex) for refractory macular edema secondary to retinitis pigmentosa. *Turk J Ophthalmol*. Aug 2016;46(4):179-181. PMID 28058154
50. Buchaim G, Rezende MP, Maia M. [Intravitreal implantation of Ozurdex(R) chronic delivery system for management of macular edema related to retinitis pigmentosa: case report]. *Arq Bras Oftalmol*. Nov-Dec 2013;76(6):377-379. PMID 24510088
51. Ahn SJ, Kim KE, Woo SJ, et al. The effect of an intravitreal dexamethasone implant for cystoid macular edema in retinitis pigmentosa: a case report and literature review. *Ophthalmic Surg Lasers Imaging Retina*. Mar-Apr 2014;45(2):160-164. PMID 24506098
52. Patil L, Lotery AJ. Coat's-like exudation in rhodopsin retinitis pigmentosa: successful treatment with an intravitreal dexamethasone implant. *Eye (Lond)*. Apr 2014;28(4):449-451. PMID 24458202
53. Saatci AO, Selver OB, Seymenoglu G, et al. Bilateral intravitreal dexamethasone implant for retinitis pigmentosa- related macular edema. *Case Rep Ophthalmol*. Jan 2013;4(1):53-58. PMID 23616764
54. Lei S, Lam WC. Efficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children. *Can J Ophthalmol*. Jun 2015;50(3):236-241. PMID 26040225
55. Loutfi M, Papathomas T, Kamal A. Macular oedema related to idiopathic macular telangiectasia type 1 treated with dexamethasone intravitreal implant (ozurdex). *Case Rep Ophthalmol Med*. 2014;2014:231913. PMID 25045562
56. Klamann A, Bottcher K, Ackermann P, et al. Intravitreal dexamethasone implant for the treatment of postoperative macular edema. *Ophthalmologica*. Dec 2016;236(4):181-185. PMID 27915343
57. Sudhalkar A, Chhablani J, Vasavada A, et al. Intravitreal dexamethasone implant for recurrent cystoid macular edema due to Irvine-Gass syndrome: a prospective case series. *Eye (Lond)*. Dec 2016;30(12):1549-1557. PMID 27858937
58. Keilani C, Halalchi A, Wakpi Djeugue D, et al. Evaluation of best-corrected visual acuity and central macular thickness after intravitreal dexamethasone implant injections in patients with Irvine-Gass syndrome: A retrospective study of six cases. *Therapie*. Oct 2016;71(5):457-465. PMID 27203164
59. Mayer WJ, Kurz S, Wolf A, et al. Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome. *J Cataract Refract Surg*. Sep 2015;41(9):1954-1961. PMID 26603404
60. Landre C, Zourdani A, Gastaud P, et al. [Treatment of postoperative cystoid macular edema (Irvine-Gass syndrome) with dexamethasone 0.7 mg intravitreal implant] [French]. *J Fr Ophtalmol*. Jan 2016;39(1):5-11. PMID 26520410
61. Degoumois A, Akesbi J, Laurens C, et al. [Efficacy of intravitreal dexamethasone implants in macular edema excluding venous occlusions: results for a cohort of 80 patients] [French]. *J Fr Ophtalmol*. Feb 2015;38(2):126- 133. PMID 25592383

62. Dutra Medeiros M, Navarro R, Garcia-Arumi J, et al. Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome. *Invest Ophthalmol Vis Sci.* May 07 2013;54(5):3320-3324. PMID 23599334
63. Bellocq D, Pierre-Kahn V, Matonti F, et al. Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine-Gass syndrome: the EPISODIC-2 study. *Br J Ophthalmol.* Mar 2017;101(3):333-341. PMID 27190126
64. Bazin L, Gambrelle J. [Combined treatment with photodynamic therapy and intravitreal dexamethasone implant (Ozurdex((R))) for circumscribed choroidal hemangioma] [French]. *J Fr Ophtalmol.* Dec 2012;35(10):798-802. PMID 23040445
65. Sherif M, Wolfensberger TJ. Intraocular dexamethasone implant as adjunct to silicone oil tamponade for proliferative vitreoretinopathy. *Klin Monbl Augenheilkd.* Apr 2017;234(4):501-504. PMID 28147403
66. Reibaldi M, Russo A, Longo A, et al. Rhegmatogenous retinal detachment with a high risk of proliferative vitreoretinopathy treated with episcleral surgery and an intravitreal dexamethasone 0.7-mg implant. *Case Rep Ophthalmol.* Jan 2013;4(1):79-83. PMID 23687501
67. Caminal JM, Flores-Moreno I, Arias L, et al. Intravitreal dexamethasone implant for radiation maculopathy secondary to plaque brachytherapy in choroidal melanoma. *Retina.* Sep 2015;35(9):1890-1897. PMID 26035401
68. Bui KM, Chow CC, Mieler WF. Treatment of recalcitrant radiation maculopathy using intravitreal dexamethasone (Ozurdex) implant. *Retin Cases Brief Rep.* Summer 2014;8(3):167-170. PMID 25372430
69. Baillif S, Maschi C, Gastaud P, et al. Intravitreal dexamethasone 0.7-mg implant for radiation macular edema after proton beam therapy for choroidal melanoma. *Retina.* Oct 2013;33(9):1784-1790. PMID 23652581
70. Tyson SL, Bafna S, Gira JP, et al. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. *J Cataract Refract Surg.* 2019 Feb;45(2). PMID 30367938
71. Walters T, Bafna S, Vold S, Wortz G, Harton P, et al. (2016) Efficacy and Safety of Sustained Release Dexamethasone for the Treatment of Ocular Pain and Inflammation after Cataract Surgery: Results from Two Phase 3 Studies. *J Clin Exp Ophthalmol* 7:1000572. doi: 10.4172/2155-9570.1000572
72. Sudhalkar A, Vasavada A, Bhojwani D, et al. Intravitreal dexamethasone implant as an alternative to systemic steroids as prophylaxis for uveitic cataract surgery: a randomized trial. *Eye (Lond).* 2019 Jul. PMID 31320735
73. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying G-s, Retinal Vein Occlusions Preferred Practice Pattern, *Ophthalmology* (2019), doi: <https://doi.org/10.1016/j.optha.2019.09.029>.
74. National Institute for Health and Care Excellence (NICE). Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy Technology appraisal guidance [TA613], 2019. <https://www.nice.org.uk/guidance/ta613> Accessed January 27, 2020.
75. National Institute for Health and Care Excellence (NICE). Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis Technology appraisal guidance [TA590] 2019; <https://www.nice.org.uk/guidance/TA590/chapter/1-Recommendations> Accessed January 27, 2020.
76. National Institute for Health and Care Excellence (NICE). Adalimumab and dexamethasone for treating non- infectious uveitis [TA460]. 2017; <https://www.nice.org.uk/guidance/ta460>. Accessed January 27, 2020.
77. National Institute for Health and Care Excellence (NICE). Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion [TA229]. 2011; <https://www.nice.org.uk/guidance/ta229>. Accessed January 27, 2020.
78. National Institute for Health and Care Excellence (NICE). Dexamethasone intravitreal implant for treating diabetic macular oedema [TA349]. 2015; <https://www.nice.org.uk/guidance/ta349>. Accessed January 27, 2020.

79. National Institute for Health and Care Excellence (NICE). Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy [TA301]. 2013; <https://www.nice.org.uk/guidance/ta301>. Accessed January 27, 2020.

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

